Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 6, 2013Pediatric Transplantation

Empiric switch from calcineurin inhibitor to sirolimus‐based immunosuppression in pediatric heart transplantation recipients

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRobert W. LoarCook Children's Medical CenterDDDavid J. DriscollChildren's Hospital of WisconsinSKSudhir S. KushwahaBaba Raghav Das Medical College

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Loar et al. (2013) studied this question.

synapsesocial.com/papers/6a72c02875498292b70bb4afhttps://doi.org/10.1111/petr.12163
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients2008 · 165 citations
  2. 2Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells1995 · 604 citations
  3. 3Sirolimus in De Novo Heart Transplant Recipients Reduces Acute Rejection and Prevents Coronary Artery Disease at 2 Years2004 · 460 citations